RPL26L1 (ribosomal protein L26 like 1) is a structural component of the cytosolic large ribosomal subunit involved in protein synthesis 1. The gene functions as a hub gene in multiple disease pathways, identified through co-expression network analyses in mantle cell lymphoma, systemic lupus erythematosus (SLE), major depressive disorder (MDD), and multiple myeloma 2345. In mantle cell lymphoma, RPL26L1 was identified as a hub gene within the ribosome pathway module associated with disease pathogenesis 2. In SLE, RPL26L1 expression levels were validated as a candidate hub gene potentially involved in disease development and immune dysfunction 3. In MDD, RPL26L1 emerged as a high-degree hub gene with potential therapeutic significance 4. RPL26L1 was identified as one of six prognostic exosome-related genes in multiple myeloma, contributing to a risk-scoring model predictive of 3-year survival (AUC=0.74-0.77) and associated with immunosuppressive microenvironment characteristics 5. Functionally, RPL26L1 perturbation impairs cardiomyocyte proliferation and cardiac development, with knockdown causing cardiac malformations in model organisms relevant to hypoplastic left heart syndrome pathogenesis 1. These findings establish RPL26L1 as a multifunctional gene with roles in ribosomal function and potential contributions to cancer prognosis, autoimmune disease, psychiatric disorders, and congenital heart disease.